Anaphylaxis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Anaphylaxis – Drugs In Development, 2024 report and make more profitable business decisions.
Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways, and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma, and family history. Treatment includes beta-agonists, antihistamines, and cortisone.
The Anaphylaxis drugs in development market research report provide comprehensive information on the therapeutics under development for Anaphylaxis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Anaphylaxis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 18 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Anaphylaxis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Anaphylaxis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Anaphylaxis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Allakos IncAquestive Therapeutics Inc
ARS Pharmaceuticals Inc
Belhaven Biopharma Inc
BioArdis LLC
Bioprojet SCR
Bryn Pharma LLC
Crossject SA
De Motu Cordis Pty Ltd
Hoth Therapeutics Inc
Klaria Pharma Holding AB
Nasus Pharma Ltd
Orexo AB
Pasteur Institute
Pediatrix Therapeutics Inc
Pharmacin BV
PureIMS BV
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Anaphylaxis reports